Toyota is taking a bold step by introducing humanoid robots at its Canadian assembly plant. While the full details remain behind a paywall, the move reflects a new phase of automation in automotive manufacturing.

Medline’s newly upgraded Relative Strength Rating offers a glimpse into its rising technical performance in the biotech and pharma space. With an 81 RS Rating, the company demonstrates improving market leadership in a competitive industry.

A strategic partnership has propelled West Chester-based Verrica Pharmaceuticals into the Japanese market, as Torii Pharmaceutical Co. Ltd. launches YCANTH for molluscum contagiosum. The approval, granted in September 2025, marks an important step in offering treatment options to patients suffering from this skin condition.

Apptronik, an AI-powered robotics company, announced a new $520 million extension round, propelling its total Series A to over $935 million. This significant investment underscores strong investor confidence in the development of the company’s humanoid robot, ApolloTM, and its vision for large-scale deployment worldwide.

Alvotech has entered key supply and commercialization agreements with Sandoz to expand biosimilar treatments in Canada and across Australia and New Zealand. The deal covers multiple therapeutic areas—ophthalmology, immunology, and gastroenterology—and positions both companies to broaden patient access through shared responsibilities in development, manufacturing, and distribution.

Two California car makers—one large, one small—recently announced their intent to expand from electric vehicles into the realm of robotics. This strategic pivot underscores both companies’ drive to innovate beyond traditional automotive manufacturing.

Pony.ai has announced a strategic partnership with Beijing ATBB Travel & Express Service Co., Ltd., geared toward expanding robotaxi services across both urban and airport settings. This move underscores Pony.ai’s leadership in large-scale mass production and commercialization of autonomous driving technology.

The global clinical mass spectrometry market is expected to reach USD 3.31 billion by 2031, signaling a profound shift toward high-specificity diagnostics. Recent findings highlight this technology’s growing influence on clinical labs worldwide, positioning it for substantial expansion.

MIT’s Associate Professor Bryan Bryson is uncovering how Myobacterium tuberculosis interacts with our immune systems, in a focus that could reshape TB vaccine strategies. By translating these biological insights into engineering solutions, Bryson hopes to help eliminate a disease that remains a global challenge.

Polymeric biomaterials have become a focal point in medical innovation, offering personalized solutions for implants, scaffolds, and drug delivery. Driven by rising demand for minimally invasive procedures, the market is expected to surpass US$16 billion by 2030, reshaping clinical care worldwide.

Cabaletta Bio is forging ahead with rese-cel, a CAR T cell therapy for autoimmune diseases, targeting a 2027 FDA submission. The Philadelphia-based biotech has mapped out an ambitious 2026 roadmap that underscores its commitment to advancing next-generation treatment options.

Scientists have revealed how mango plants activate a powerful antioxidant system to shield themselves from harmful ultraviolet-B (UV-B) rays. This cutting-edge discovery could pave the way for stronger, more resilient tropical crops in the future.

Shares of Atossa jumped 10% before regular trading hours, tied to the announcement of Orphan Drug Designation. This special status, granted to products for rare diseases, often provides key competitive benefits and regulatory incentives.

Scientists have recreated ancient enzymes that once helped cannabis produce multiple cannabinoids simultaneously. Their work reveals how today’s specialized THC, CBD, and CBC pathways originated from more robust, multitasking enzyme systems millions of years ago.

A father-son team from South Africa has reclaimed the Guinness World Record for the fastest quadcopter drone. Their Peregreen V4, a 3D-printed marvel, soared to an astonishing 408 mph, showcasing the incredible potential of cutting-edge drone technology.

A major trade show in Las Vegas underscores the growing prominence of robots and artificial intelligence in modern technology. Industry experts highlight the new wave of automation, prompting observers to echo a simple mandate: “Make way for the robots.”

Boston Dynamics unveiled its remarkable Atlas humanoid robot at CES 2026 in Las Vegas, showcasing years of refinement. With dexterity that continues to advance and AI innovations playing a key role, Atlas seems poised to tackle workplace tasks sooner rather than later.

XRlabs is developing a cutting-edge platform using NVIDIA Jetson Thor and NVIDIA Isaac to modernize surgical scopes. Through real-time AI analysis, vision-based tool tracking, and intent-aware automation, this initiative promises to optimize operating room workflows and improve clinical outcomes.

Nvidia is determined to integrate AI into the real world with new models unveiled at CES 2026. The company introduced Cosmos Reason 2, an updated vision-language model for embodied reasoning, alongside an expanded Nemotron family that aims to supercharge robotic intelligence.

Europol warns that crime involving humanoid robots could become widespread by 2035, fueled by the public’s growing unease. A new report suggests that without thoughtful intervention, hostility toward robots may escalate into widespread violence.

Around 450 squirrel-sized marmosets at Texas Biomed’s primate center in San Antonio are helping researchers unlock the mysteries of aging, health span, and longevity. Their unexpected sweet tooth for marshmallows adds a lighthearted twist to a serious scientific endeavor.